Trial Profile
A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçets Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Behcet's syndrome; Panuveitis; Posterior uveitis
- Focus Registrational; Therapeutic Use
- Acronyms SHIELD
- Sponsors Novartis
- 19 Feb 2016 Primary endpoint for extension trial has been amended as reported by ClinicalTrials.gov record.
- 20 Jul 2011 New trial record